AIM ImmunoTech Raises $1.8M via $1,000 Rights Offering Units with Warrants
AIM ImmunoTech closed a $1.8 million rights offering with subscriptions at $1,000 per unit, generating approximately 1,800 units sold. Each unit comprises one Series G Convertible Preferred Share and 2,000 Class G Common Stock Purchase Warrants.
1. Rights Offering Closure
On March 6, 2026, AIM ImmunoTech closed its previously announced rights offering, securing approximately $1.8 million through unit subscriptions priced at $1,000 each. The offering was conducted under an effective SEC registration statement, facilitating rapid access to funding within a structured framework.
2. Unit Composition
Each unit issued consists of one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants. Holders of the Warrants have the right to purchase common shares under terms outlined in the company’s registration statement.
3. Funding Outlook
Proceeds from the rights offering are earmarked to support ongoing clinical trials of Ampligen and general corporate purposes, extending the company’s financial runway. This infusion bolsters the balance sheet ahead of key development milestones for late-stage pancreatic cancer treatment research.